Katmai Oncology Group — Anchorage, Alaska

Public research footprint of Katmai Oncology Group, compiled from the ClinicalTrials.gov public registry.

243

Registered studies

156

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 · Recurrent Ovarian Carcinoma · Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type · Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma

Recently updated registry entries

NCT02196181 — Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer… (Active Not Recruiting)
NCT03712605 — Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After… (Active Not Recruiting)
NCT04708418 — A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Katmai Oncology Group?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.